Andrew Cournoyer, RPh, MBA; Larry Blandford, PharmD—Column Editor

Annual updates to formulary exclusion lists suggest a need for careful evaluation by benefit sponsors, clinicians, patient advocacy groups, and the pharmaceutical industry to determine implications on treatment outcomes and achieving value-based care.
Authors discuss how the use of formulary exclusion lists is expanding and what this trend means for different patient populations and payer organizations.